ArticleThe Prostate2023

Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.

Ali T Arafa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.